Phase 2 Depression and Anxiety Trial, Recruiting NCT07300969 Sponsor: Draig Therapeutics Ltd Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, Recruiting

NCT07300969
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who can read, understand, and communicate in the local language used at the trial site, and who are willing to sign a consent form.
  • People aged 18 to 75 years old (inclusive) at the time of signing the consent form, of any gender identity.
  • People who have been diagnosed with recurring depression (meaning at least one previous episode of depression before the current one), based on the DSM-5-TR, which is the standard medical guide used to diagnose mental health conditions.

Who may not be able to join:

  • People who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • People who have an unstable medical condition or a chronic (long-term) illness that is not well controlled.
  • People who have a significant problem affecting how the brain or nervous system works.
  • People who have had moderate or severe problems with alcohol or drug use (as defined by the DSM-5-TR) in the six months before the screening visit.
  • People who have a history of seizures.
  • People whom the trial investigator believes would have difficulty following the study's requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +44(0)2920028450

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Draig Therapeutics Ltd
Registry
ClinicalTrials.gov
Start date
16 December 2025
Est. completion
1 August 2027

Where this trial is recruiting

🇧🇬 Bulgaria 🇨🇿 Czechia 🇵🇱 Poland 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 42

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov